---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-020615"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2021-08-19T23:59:59+00:00"
generated_at: "2026-06-29T08:49:44.534019+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M

## Summary
- FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.
- Q2 2021 net loss $2.6M (vs $0.6M in Q2 2020); G&A expense rose to $2.2M.
- Closed $13.2M public offering of 3.18M units at $4.15/unit; cash $11.9M as of June 30, 2021.
- Initial Phase I/IIa data readout expected 1H 2022, final readout Q3 2022.

## SEC filing metadata
- accession: 0001493152-21-020615
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2021-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/0001493152-21-020615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-020615
- JSON: https://secwatch.observer/filing/0001493152-21-020615.json
- Plain text: https://secwatch.observer/filing/0001493152-21-020615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.